- Natera Inc. (NTRA, Financial) announced results from the largest sarcoma study using cell-free DNA analysis, showing high sensitivity and specificity for their Signatera test.
- The study indicated an overall sensitivity of 89% and specificity of 100% for detecting sarcoma recurrence.
- In leiomyosarcoma, a common subtype, the sensitivitiy reached 93% with a specificity of 100%, showcasing Signatera's efficacy in monitoring treatment response.
Natera, Inc. (NTRA), a leading company in precision medicine and cell-free DNA testing, has unveiled findings from the largest sarcoma study to date utilizing cell-free DNA analysis. Conducted by Stanford University School of Medicine, the study assessed Signatera, Natera's personalized molecular residual disease (MRD) test, in patients diagnosed with soft tissue and bone sarcomas. The research involved over 2,100 samples from more than 200 patients, making it the most comprehensive study of its kind.
Signatera demonstrated an impressive performance, achieving an overall sensitivity of 89% and a specificity of 100%. In leiomyosarcoma patients, the most prevalent subtype in the cohort, the test's sensitivity was 93%, while maintaining a specificity of 100%. The study's findings, presented at the 2025 Society of Surgical Oncology Annual Meeting, underscore the potential of Signatera in tracking treatment responses noninvasively and improving patient care.
Dr. Beatrice J. Sun from Stanford University remarked on the significance of the data, stating, "This data represents a major step forward in understanding how ctDNA monitoring can be applied across a diverse range of sarcoma subtypes." The results suggest that Signatera can enhance personalized care by offering precise monitoring of disease recurrence and treatment responses.
Natera's commitment to advancing cancer diagnostics is further evidenced by their plans to launch a prospective study to explore Signatera's clinical utility in guiding treatment decisions for sarcoma patients. This study builds on Natera's broader goal of making personalized genetic testing a standard part of patient care, promoting earlier, targeted interventions.
